 |
市場調查報告書
結核檢驗的市場規模(2020年∼2027年)Global Tuberculosis Testing Market - 2020-2027 |
||||||
| 出版商 | DataM Intelligence | 商品編碼 | 955344 | ||||
| 出版日期 | 按訂單生產 | 內容資訊 | 英文 商品交期: 請詢問到貨日 |
||||
| 價格 |
|
||||||
| 結核檢驗的市場規模(2020年∼2027年) Global Tuberculosis Testing Market - 2020-2027 | ||
| 出版日期: 按訂單生產 | 內容資訊: 英文 |
|
結核(TB)檢驗的市場規模的擴大要素，是結核和多重抗藥性結核的負擔增加，研究開發投資的增加，集中性的產品平台，新興國家市場上政府的配合措施增加等。以結核診斷藥為中心環境，這個10年戲劇性地改變。結核的盛行率年年增加，政府的啟發計劃數也增加，人們採用診斷檢驗(X光檢查等)，在在預測期間內促進市場成長。
本報告提供全球結核檢驗市場的相關調查，市場機會，成長及阻礙因素，各檢驗類型、終端用戶、地區的市場分析，競爭情形，主要企業的簡介等資訊。
Tuberculosis (TB) is a communicable disease that is a major cause of ill health, one of the top 10 causes of death worldwide and the leading cause of death from a single infectious agent. It is caused by the bacillus Mycobacterium tuberculosis, which is spread when people who are sick with TB expel bacteria into the air; for example, by coughing. It typically affects the lungs (pulmonary TB) but can also affect other sites. About a quarter of the world's population is infected with M. tuberculosis and thus at risk of developing TB disease. Tuberculosis testing can be defined as the most commonly used diagnostic tools for the tuberculosis. With a timely diagnosis and treatment with first-line antibiotics for 6 months, most people who develop TB can be cured and onward transmission of infection curtailed. The number of TB cases occurring each year can also be driven down by reducing the prevalence of health-related risk factors for TB providing preventive treatment to people.
The market is driven by the increasing number of coronavirus cases which has increasing number of tuberculosis patients. According to the World Health Organization (WHO), in 2017, an estimated 4.4 million people fell ill with TB and an estimated 638,000 died because of the disease which is more than half of global TB deaths. Factors propelling the growth of the market include the increasing burden of tuberculosis and multidrug-resistant tuberculosis, increasing R&D investments, intensive product pipelines, and increasing government initiatives in the emerging markets. The landscape of TB diagnostics has changed dramatically during the past ten years. Moreover, in response to WHO Global TB program, it has implemented a systematic and dynamic process, that is used to evaluate technologies and develop policies, which has, thus, enhanced the growth of the market.
The prevalence rate of tuberculosis is also increasing every year, along with the number of government awareness programs that are influencing people to opt for diagnostic tests (like radiographic tests), which are expected to drive the market during the forecast period. The market is also expected to witness growth as there is an opportunity for players in the market studied to accelerate the market approval of their pipeline diagnostic products by spurring the fundamental research in TB. Additionally, technological developments in fields, like genomics and proteomics, can be leveraged by diagnostic providers to hasten the process of product development in TB diagnostics.
The increasing screening rate in the high burden regions, affordability of diagnostics, advanced methodologies, faster clinical decisions, and reduction in mortality rate are the focal areas of development. Improved preventive and curative diagnosis rates are the end results of these initiatives. This has led to a subsequent upsurge in the demand for diagnostic tests and the TB diagnostics market.
Furthermore, the government and independent healthcare organizations have undertaken initiatives to control the proliferation of this infectious disease. Creating awareness about the importance of diagnosis is vital in increasing the screening and diagnosis rates, further helping the TB diagnostics market to flourish. This factor is driving the growth of the market in the forecast period. For instance, the Revised National Tuberculosis Control Program (RNTCP) in India focuses on performing TB screening and providing greater access to treatment through free diagnosis & treatment programs. In addition, private-public partnerships under this program are boosting the diagnosis rate.
Population above the age of 60 years is the target population for the TB diagnostics market as this demographic is susceptible to infectious diseases. The growing geriatric population base, as a result, is driving the growth of the market.
However, drug resistance in tuberculosis is one of the primary concerns for healthcare professionals as improper treatment due to wrong drug regimen and incorrect dosage forms lead to the development of drug resistance in TB patients undergoing treatment. Which is restraining the growth of the market.
The global tuberculosis testing market is segmented based on test type by Cytokine Detection Assay, Nu��l迮I�� �𣌊�Id 苠迮stIng, Detection of Latent Infection, 苤ultur迮 �𠸝酒迮d 苠迮sts, Drug Sus��迮��tIbIlIt�� 苠迮stIng, and �𣳼h迮rs. The Nu��l迮I�� �𣌊�Id 苠迮stIng segment held the largest market share due to its use as diagnostic tools for tuberculosis (TB) from many years, and which still continue to be used. There are substantial advancements in the diagnosis of TB. Moreover, these tests have been commercially available in the United States for over two decades that offer better accuracy than other microscopy tests, and even provide greater speed than culture-based tests. A nucleic acid test, for tuberculosis (TB) is a molecular test used to detect the DNA (deoxyribonucleic acid) of Mycobacterium tuberculosis complex (MTBC) in a sputum or other respiratory sample. Because the amount of DNA in a sample is very small, NAA testing includes a step that amplifies (or copies) the genetic material. Polymerase Chain Reaction (PCR) is a common form of nucleic acid test used in laboratory diagnosis.
Drug Sus��迮��tIbIlIt�� 苠迮stIng is expected to have positive market growth because they are cost efficient and easy-to-perform. The high burden regions rely on these methodologies due to their financial and technical incapability to incorporate advanced technologies thus contributing to the growth of the market
A Cytokine Detection Assay is usually employed to check for the specific cytokines being secreted. This is more a function of biochemistry research rather than a specific test for body functions. Cytokines and their receptors are under a great deal of research because of their role in disease control. It is worth noting that many cytokines have an opposing and sometimes complimentary effect to each other; thereby, modulating the severity of the immune response. Cytokine assays are used to identify which cytokines and their deficiencies are responsible for the cause of some autoimmune diseases.
A Detection of Latent Infection The goal of testing for LTBI is to identify individuals who are at increased risk for the development of tuberculosis (TB) and therefore who would benefit from treatment of latent TB infection. Only those who would benefit from treatment should be tested, so a decision to test presupposes a decision to treat if the test is positive. This factor would drive the growth of market in the forecast period.
According to WHO in 2018, globally 65 countries reported initiating TB preventive treatment for 1.8 million people from just under 1 million in 2017. The 2018 number suggests that the target of 6 million people in the period 2018-2022 can be achieved. Funding for the provision of TB prevention, diagnostic and treatment services has doubled since 2006 but still falls far short of what is needed.
Further, the market is also classified based on End-User as Hospital laboratories, Research laboratories, Clinics laboratories, Diagnostic center. The hospital laboratories segment accounts for the highest market share due to the cost effective tests available in hospitals. As per the CDC around 9.105 TB cases (2.8 cases per 100,000 persons) were suffering from TB in 2017. In 2017 only total 1600,000 deaths were reported due to the TB. After this increasing number of the TB patients all over the world the demand of hospital is increasing. Each hospital laboratory manages its own purchases tender for large equipment purchases and at the discretion of the lab manager for smaller purchases. Each hospital lab has a global budget, there is no fee for service. This factor drive the growth of the market in the forecast period.
The clinics laboratories have positive growth during the forecast period due to the primary need is for simple confirmatory or screening tests for use in clinics to distinguish active tuberculosis from all other conditions that may cause the same symptoms. Tests are also needed to monitor treatment response, to determine whether there is bacterial resistance to specific drugs and to detect latent infection in people at greatest risk for progression to active TB following exposure. In rural settings and smaller clinics laboratories, human and financial resource limitations render the implementation of sophisticated technologies impossible, even if they are otherwise attractive. These smaller clinics laboratory on the periphery of the health system are, however, where the vast majority of TB suspects initially seek care. These factors are driving the growth of the market in the forecast period.
By Region, the global tuberculosis testing market is segmented into North America, South America, Europe, Asia-Pacific, Middle-East, and Africa. Among all of the regions, Asia-Pacific dominated the global tuberculosis testing market and is expected to grow at the highest CAGR during the forecast period. The growth of the market in the Region is attributed to the high burden of tuberculosis as well as the rapid proliferation of this disease. The increasing prevalence of TB in Japan helps in the growth of the TB diagnostics market, as the high prevalence of TB creates an urgent demand for effective and quick diagnosis of the disease. In addition, in countries such as India, according to the recent budget announcement, Government of India aims to eliminate tuberculosis by 2025, which is expected to act as one of the major factor for the growth of the Asia-Pacific market during the forecast period.
Infectious and Endemic Disease Control in China, RNTCP in India, and National TB program in Afghanistan are the few programs planned by local healthcare agencies to contain the incidence and ensure equitable access to diagnosis for this disease. As per the WHO, countries such as India, China, Afghanistan, and Indonesia are priority regions for control of this communicable disease.
The Middle East and Africa region is expected to have third-largest share due to the relatively faster pace because of the increasing instances of tuberculosis. The increasing government focus on establishing regulations for the approval of tuberculosis tests, and growing focus on awareness programs by the tuberculosis diagnosis testing kits manufacturing companies, among others. In North America powered by the U.S. is one of the major market for global tuberculosis testing market.
In October 2018, BD a leading global medical technology company, announced the availability of the BD MAX™ MDR-TB panel in Europe. BD launched the first automated liquid culture system, the BD BACTEC™ MGIT™ system for comprehensive testing for drug susceptibility and resistance.
The global tuberculosis testing market is highly competitive, with the presence of several international and local markets. Product diversification, revenue generation, and opportunities intensify the market competition. Thermo Fisher Scientific, Inc., Hologic Corporation, Abbott Laboratories, Alere, Inc., Becton, Dickinson and Company, F. Hoffmann-La Roche AG, bioMerieux SA, Sanofi, Cepheid, Hain Lifescience GmbH,are the leading market players with significant market share. The major players are using product development, novel product launches, market expansion, and product diversification strategies for holding their position in the market.
The companies are entering into collaborations, mergers, strategic partnerships, and acquisitions to expand their presence and meet the rising demand for the Treatment of COVID-19 across the globe.
For instance, in July 2016, bioMerieux launched a novel CE marked database and reagents kit VITEK MS for the identification of TB. This new product launch is anticipated to help the company increase its market share.
In September 2017, Thermo Fisher Scientific, Inc. acquired Alfa Aesar for USD 400 million. Alfa Aesar is involved in providing laboratory and research chemicals ranging from catalysts, reagents, analytical, and labeling products. Their combined strength in laboratory chemical development and production is expected to support their growth in this sector.
Target Audience2022
